OCS
Oculis Holding AG Ordinary shares
NASDAQ: OCS · HEALTHCARE · BIOTECHNOLOGY
$27.48
+3.89% today
Updated 2026-04-30
Market cap
$1.57B
P/E ratio
—
P/S ratio
1,311.54x
EPS (TTM)
$-2.40
Dividend yield
—
52W range
$16 – $31
Volume
0.4M
Oculis Holding AG Ordinary shares (OCS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $993000.00 | $960000.00 | $912000.00 | $883000.00 | $686000.00 | $0.00 |
| Revenue growth (YoY) | — | -3.3% | -5.0% | -3.2% | -22.3% | -100.0% |
| Cost of revenue | $9.34M | $9.57M | $22.22M | $29.25M | $52.08M | — |
| Gross profit | $-8.34M | $-8.61M | $-21.31M | $-28.36M | $-51.40M | — |
| Gross margin | -840.3% | -896.7% | -2336.8% | -3212.2% | -7492.3% | — |
| R&D | $9.34M | $9.57M | $22.22M | $29.25M | $52.08M | $54.52M |
| SG&A | $3.52M | $4.10M | $6.74M | $14.72M | $21.81M | $23.20M |
| Operating income | $-12.34M | $-13.23M | $-32.38M | $-80.71M | $-73.20M | $-79.15M |
| Operating margin | -1242.3% | -1378.3% | -3550.0% | -9140.9% | -10671.1% | — |
| EBITDA | $-12.10M | $-13.17M | $-31.90M | $-87.09M | $-72.80M | $-79.15M |
| EBITDA margin | -1218.2% | -1371.8% | -3498.0% | -9863.3% | -10612.0% | — |
| EBIT | $-12.32M | $-13.40M | $-32.20M | $-87.38M | $-73.20M | — |
| Interest expense | $2.63M | $5.12M | $6.44M | $1.46M | $639000.00 | $795550.00 |
| Income tax | $83000.00 | $27000.00 | $55000.00 | $107000.00 | $-160000.00 | — |
| Effective tax rate | -0.6% | -0.1% | -0.1% | -0.1% | 0.2% | 0.0% |
| Net income | $-14.87M | $-18.55M | $-38.70M | $-88.80M | $-85.78M | $-94.51M |
| Net income growth (YoY) | — | -24.7% | -108.6% | -129.5% | +3.4% | -10.2% |
| Profit margin | -1497.8% | -1932.5% | -4243.2% | -10056.9% | -12503.9% | — |